In­ves­ti­ga­tors prep PhI­II in ef­fort to move MD­MA (you know it as ec­sta­sy) off the street and in­to use for PTSD

Over the past few years there has been a grow­ing push to study the ef­fi­ca­cy of il­lic­it drugs for a range of neu­ropsy­chi­atric con­di­tions. And now a group of in­ves­ti­ga­tors are re­port­ed­ly prep­ping a Phase III tri­al of MD­MA, bet­ter known on the street as ec­sta­sy, for post trau­mat­ic-stress dis­or­der.

The Mul­ti­dis­ci­pli­nary As­so­ci­a­tion for Psy­che­del­ic Stud­ies is un­der­tak­ing the study, ac­cord­ing to The New York Times, which did an in-depth fea­ture on the drug and its slow progress in the clin­ic. MAPS, a non­prof­it fu­eled by do­na­tions, has been ad­vo­cat­ing for the clin­i­cal use of a range of psy­che­delics like MD­MA and LSD, as well as mar­i­jua­na, but on­ly af­ter a rig­or­ous sci­en­tif­ic re­view. And it can cite Phase II da­ta that in­di­cate MD­MA can end PTSD symp­toms that af­flict a large per­cent­age of pa­tients.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.